CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today its key pipeline, scientific and business goals for the next 12 to 18 months, including 2010 financial guidance.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today its key pipeline, scientific and business goals for the next 12 to 18 months, including 2010 financial guidance.
